engleski

DEHYDRATECH-CBD DIETARY SUPPLEMENT AND EFFECT ON HYPERTENSION

Cannabidiol (CBD) is a bioactive cannabinoid with non-psychotropic effects and is consumed as food supplement by millions of people today. DehydraTECH-CBD is patented capsule formulation (developed by Lexaria Bioscience Corp.) that increases the bioabsorption of the active content due to its enhanced lipophilic composition by bypassing (or reducing) first-pass liver metabolism. It was conducted as a double-blinded, placebo- controlled, cross-over pilot study in which 24 eligible volunteers (12 males and 12 females) were recruited and completed all experimental parts. The aim of that study was to extend the findings of DehydraTECH-CBD on cardiovascular system in humans with mild or moderate untreated hypertension. Each participant received in a randomized and double-blinded order CBD or DehydraTECH-CBD (12 capsules with 300 mg of active substance). Blood pressure and heart rate were measured in triplicate every 10 minutes throughout the study. Three venous blood samples were taken: at baseline and in the 120th and 180th minutes. CBD concentration was determined by a GC-MS/MS system. Our results have showed that in the subset of volunteers who were Stage 2 hypertensive, peak systolic BP reductions from baseline were observed of as much as approximately 13 mmHg by the 50- minute time point with DehydraTECH-CBD, and systolic BP remained depressed throughout almost the entire 3-hour duration of the study. We can conclude that DehydraTECH technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure.

blood pressure ; Canabidiol ; food suplements ; GC/MS method ; liver metabolism

nije evidentirano